Glenn Rogers is a longtime contributor for BuildingWealth.ca (http://www.buildingwealth.ca). His background is in Media and Publishing and has held a number of senior positions in major magazine and newspaper organizations. He has also successfully partnered with private equity firms to acquire,... More
Perrigo Company (NDQ: PRGO) Originally recommended on June 22/09 (IWB #2923) at $26.81. Closed Friday at $36.77. (All figures in U.S. dollars.) The shares in this generic drug maker closed on Friday at $36.77 which means we are ahead 37.2% since my June recommendation, including a dividend of 5.5c a share received in August. The company is due to release first quarter 2010 results on Nov. 2, so certainly hold the stock until the earnings report comes out. Perrigo has filed for permission to produce a genericversion of Rogaine which, if granted, could have a very positive impact on the company's outlook. In other good news, Perrigo was released from a lawsuit that had been brought against them by Stiefel Laboratories which is a division of Glaxo SmithKline. This stock and TEVA are two of my favorite generic drug plays and are particularly attractive given the context of the Obama healthcare program that is likely to be approved by Congress in the coming months. It is very likely that the use of generic drugs will be specified in the legislation so both Perrigo and TEVA should be long-term beneficiaries. Action now: Hold.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha
community. Instablog posts are not selected, edited or screened by Seeking Alpha editors,
in contrast to contributors' articles.
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
Hold on to Perrigo 0 comments
Originally recommended on June 22/09 (IWB #2923) at $26.81. Closed Friday at $36.77. (All figures in U.S. dollars.)
The shares in this generic drug maker closed on Friday at $36.77 which means we are ahead 37.2% since my June recommendation, including a dividend of 5.5c a share received in August. The company is due to release first quarter 2010 results on Nov. 2, so certainly hold the stock until the earnings report comes out.
Perrigo has filed for permission to produce a genericversion of Rogaine which, if granted, could have a very positive impact on the company's outlook. In other good news, Perrigo was released from a lawsuit that had been brought against them by Stiefel Laboratories which is a division of Glaxo SmithKline.
This stock and TEVA are two of my favorite generic drug plays and are particularly attractive given the context of the Obama healthcare program that is likely to be approved by Congress in the coming months. It is very likely that the use of generic drugs will be specified in the legislation so both Perrigo and TEVA should be long-term beneficiaries.
Action now: Hold.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Latest Followers
Posts by Ticker
Posts by Themes